You are here : Home > BAL team > Main funding of the team

Main funding of the team

Published on 5 May 2022

Towards personalized medicine in a rare vascular genetic disease: Hereditary Hemorrhagic Telangiectasia (HHT)

Association Maladie de Rendu-Osler (AMRO) 2022-2023 (Rendu-Osler Disease Association)

"Tremplin international 2021": Nicolas Ricard (UMR_S 1292 Grenoble/A Randi (Hammersmith Hospital, London): ALK1 expression regulation by ERG: toward new therapeutic targets to treat HHT ( RegAL)

Team FRM 2021-2024: "Respective roles of BMP9 and BMP10 in vascular homeostasis and rare vascular pathologies: Rendu-Osler disease and pulmonary hypertension"

2021-2025 ANR: SMAD4pathy (Mécanismes pathogéniques associés aux anomalies cardiovasculaires dans les SMAD4pathies)

H2020 Marie Skłodowska-Curie Actions, VA Cure (EU-funded international training network aiming to uncover core mechanisms of initiation and maintenance of Vascular Anomalies). VA Cure presentation.

2021-2025 ANR JC N. Ricard: ENQUIRE (Mechanisms of endothelial quiescence: towards new targets in Rendu-Osler diseas